Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95

Rhea-AI Filing Summary

LB Pharmaceuticals Inc director granted stock options as part of equity compensation. Director William P. Kane Jr received options for 10,000 shares of common stock, giving him the right to buy those shares at an exercise price of $27.95 per share until June 2, 2036.

According to the filing, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, if he continues to serve through that date. After this grant, he holds options for 10,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kane William P Jr

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 10,000 options Exercise price: $27.95 per share Expiration date: June 2, 2036 +3 more

6 metrics

Option grant size 10,000 options Stock Option (Right to Buy) granted to director

Exercise price $27.95 per share Conversion or exercise price for options

Expiration date June 2, 2036 Option expiration for director grant

Underlying shares 10,000 shares Common Stock underlying the option grant

Vesting date trigger June 3, 2027 or next annual meeting 100% vesting contingent on continuous service

Post-grant option holdings 10,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "27.9500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares underlying the option vest on the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kane William P Jr

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NEW YORK 10119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.95	06/03/2026		A		10,000		(1)	06/02/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Marc Panoff, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LB PHARMACEUTICALS INC (LBRX) report for William P. Kane Jr?

LB Pharmaceuticals reported that director William P. Kane Jr received a grant of stock options for 10,000 shares of common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.

What are the key terms of the LBRX stock options granted to William P. Kane Jr?

The grant covers options for 10,000 shares of LB Pharmaceuticals common stock at an exercise price of $27.95 per share. The options expire on June 2, 2036 and represent a long-dated equity incentive award for the director.

When do the newly granted LBRX stock options to William P. Kane Jr vest?

All 10,000 underlying shares vest 100% on the earlier of June 3, 2027 or the date of LB Pharmaceuticals’ next annual meeting of stockholders. Vesting requires William P. Kane Jr to maintain continuous service with the company through that vesting date.

Is the LBRX Form 4 transaction a stock purchase or a compensation award?

The Form 4 shows a compensation-related award, not an open-market stock purchase. William P. Kane Jr received a grant of stock options coded as a grant, award, or other acquisition, with no cash price paid per option on the grant date.

How many LBRX derivative securities does William P. Kane Jr hold after this Form 4 transaction?

After the reported transaction, William P. Kane Jr holds stock options for 10,000 underlying shares of LB Pharmaceuticals common stock directly. This count reflects his position in the granted options following the award reported in the Form 4.